Correlation of pretreatment 18F-FDG uptake with clinicopathological factors and prognosis in patients with newly diagnosed diffuse large B-cell lymphoma
Honghui Huang(Shanghai Jiao Tong University), Jianmin Wang(Changhai Hospital), Lan Xu(Shanghai Jiao Tong University), Luying Zheng(Creative Commons), Jia Liu(Peking University), Jianyi Zhu(Creative Commons), Yi Fang(Tongji University), Jianjun Liu(University of Kentucky), Qiang Liu(Sun Yat-sen University), Xiaofeng Han(Creative Commons), Fangyuan Chen(Zhejiang Chinese Medical University), Fei Xiao(Creative Commons), Lu Zhong(Renji Hospital), Yumei Chen(Jiangsu University), Yiping Shi(Creative Commons), Minyue Zhang(Creative Commons), Lijing Shen(Creative Commons), Beiwen Ni(Creative Commons), Ting Wang(Xijing Hospital), Hua Zhong(Creative Commons)
Cited by 21
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Large-scale genotyping identifies 41 new loci associated with breast cancer risk
|Nature Genetics|2013|1.1k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies
|JNCI Journal of the National Cancer Institute|2010|716